Last reviewed · How we verify

NCT03322176

Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing

Status unknown Last updated 23 January 2019
What this trial tests

trial testing Genetic testing in Colon Cancer in 200 participants. Status unknown.

Timeline
17 October 2017
Primary endpoint
17 October 2020
1 November 2020

Quick facts

Lead sponsorData Collection Analysis Business Management
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date17 October 2017
Primary completion17 October 2020
Estimated completion1 November 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Data Collection Analysis Business Management

Who can join

Adults 18 to 64, any sex, with Colon Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Increase surveillance for LYNCH Syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Genetic testing

Trials testing the same drug.

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

Other Data Collection Analysis Business Management trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03322176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing